GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GGNNQ) » Definitions » Dividend Payout Ratio

GGNNQ (Genocea Biosciences) Dividend Payout Ratio : 0.00 (As of Mar. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Genocea Biosciences Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Genocea Biosciences's Dividend Payout Ratio for the months ended in Mar. 2022 was 0.00.

The historical rank and industry rank for Genocea Biosciences's Dividend Payout Ratio or its related term are showing as below:


GGNNQ's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.48
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-12-12), the Dividend Yield % of Genocea Biosciences is 0.00%.

Genocea Biosciences's Dividends per Share for the months ended in Mar. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Genocea Biosciences Dividend Payout Ratio Historical Data

The historical data trend for Genocea Biosciences's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Dividend Payout Ratio Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genocea Biosciences's Dividend Payout Ratio

For the Biotechnology subindustry, Genocea Biosciences's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genocea Biosciences's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Dividend Payout Ratio falls into.



Genocea Biosciences Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Genocea Biosciences's Dividend Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2021 )/ EPS without NRI (A: Dec. 2021 )
=0/ 0
=N/A

Genocea Biosciences's Dividend Payout Ratio for the quarter that ended in Mar. 2022 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2022 )/ EPS without NRI (Q: Mar. 2022 )
=0/ 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genocea Biosciences (OTCPK:GGNNQ) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Genocea Biosciences Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
Executives
John Lunger director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Gisela Schwab director 6701 KAISER DRIVE, FREMONT CA 94555
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Girish N Aakalu officer: CHIEF BUSINESS OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Narinderjeet Singh officer: SENIOR VP, PS&M C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Pamela Carroll officer: SVP IMMUNO-ONCOLOGY C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Thomas Andrew Davis officer: CHIEF MEDICAL OFFICER 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Derek M Meisner officer: SENIOR VP AND GENERAL COUNSEL C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michael Alfieri officer: Principle Financial Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Howard Mayer director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140

Genocea Biosciences Headlines

From GuruFocus

Q1 2019 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q4 2018 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q4 2020 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2020 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-23-2022

Genocea Biosciences to Host Investor Webinar

By GuruFocusNews GuruFocusNews 04-04-2022

Q1 2021 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 07-03-2022